Risk-Adapted Donor Selection in Patients with Acute Myeloid Leukemia.
Abstract
Background
The optimal donor for adults with acute myeloid leukemia (AML) who lack a matched sibling donor (MSD) remains uncertain in Asian practice, where antithymocyte globulin (ATG)-based graft-versus-host disease (GvHD) prophylaxis is common.
Objectives
To compare outcomes after MSD, matched unrelated donor (MUD), mismatched unrelated donor (MMUD), and haploidentical donor (HID) transplantation, and to test whether disease risk modifies the donor effect. STUDY
Design
We analyzed 1,963 adults with AML who underwent first allogeneic hematopoietic stem cell transplantation (HSCT) in the Taiwan Blood and Marrow Transplantation Registry between 2009 and 2025. We applied a doubly robust strategy combining multinomial propensity-score inverse probability of treatment weighting (IPTW) with multivariable Cox and Fine-Gray regression. GvHD was evaluated as a mediator by landmark and causal mediation analyses.
Results
Using MUD as reference, all three other donor types had inferior overall survival (OS), reaching significance for HID (hazard ratio [HR] 1.34, p=0.022) and MMUD (HR 1.31, p=0.026) but not for MSD (HR 1.18, p=0.131). Non-relapse mortality (NRM) was higher after HID (HR 1.61, p=0.011), with a trend after MMUD (HR 1.38, p=0.079), and GvHD-free, relapse-free survival (GRFS) was inferior after MSD (HR 1.40, p<0.001) and HID (HR 1.31, p=0.008). Relapse did not differ by donor type, indicating that the survival advantage of MUD operates through lower NRM. Causal mediation analysis did not attribute the MUD-HID survival difference to GvHD. Disease risk modified the donor effect on OS (interaction p=0.028). In high/very-high-risk disease, MUD was superior to MSD, MMUD, and HID (HR 1.44, 1.78, and 1.74, respectively), with 3-year OS of 42.7% after MUD and 28.5% after other donors. In low/intermediate-risk disease, OS did not differ by donor type.
Conclusions
MUD was associated with better OS than alternative donors (MMUD and HID) through lower NRM, and its survival benefit was largest in high-risk disease. Donor selection in AML can be risk-adapted: MUD could be prioritized in high-risk disease, whereas GRFS should guide donor choice in lower-risk disease, where OS is similar across donor types.